Clinical trials
Borderline Personality Disorder trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2015 | 2 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Unknown status | 7 |
| Recruiting | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 4 |
| Universitat Jaume I | 3 |
| Boehringer Ingelheim | 1 |
| Consorci Sanitari del Maresme | 1 |
| Eli Lilly and Company | 1 |
| Hospital San Carlos, Madrid | 1 |
| Hospital Universitari Vall d'Hebron Research Institute | 1 |
| Hospital Vall d'Hebron | 1 |
| Oryzon Genomics S.A. | 1 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Borderline Personality Disorder | 19 |
| Alcoholism | 1 |
| Attention Deficit Disorder with Hyperactivity | 1 |
| Compulsive Personality Disorder | 1 |
| Mental Disorders | 1 |
| Personality Disorders | 1 |
| Wounds and Injuries | 1 |
Trials
Showing 51 to 19 of 19. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.